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PDB4
EFFECT OF A POLICY CHANGE ON USE OF 
BLOOD GLUCOSE MONITORS BY DIABETICS 
WITH MEDICARE COVERAGE
Silverman BG
Health Care Financing Administration, Baltimore, MD, USA
OBJECTIVE: To study the impact of a Medicare policy
change, effective July 1998, extending coverage for glu-
cose test equipment to all diabetics, including those not
using insulin. METHODS: Using a file of 5% of Medi-
care beneficiaries, we identified those with continuous
fee-for-service coverage from 1996-1998 and a diabetes
diagnosis on inpatient or physician claims in 1997. Mon-
itor and test strip use was determined by allowed claims
in the durable medical equipment claim files. RESULTS:
We identified 163,990 diabetic subjects (estimated preva-
lence among Medicare beneficiaries, 14%). Fourteen per-
cent of diabetics were estimated to have used glucose
monitors prior to January 1997; an additional 6.1% had
new monitor claim(s) between January 1997 and Decem-
ber 1998. From July through December 1998, mean
number of new monitor users per month was nearly tri-
ple that observed prior to July 1998. Nearly all of those
beginning monitor use between January 1997 and June
1998 had claim modifiers indicating insulin dependence,
compared to 59% of new users between July and Decem-
ber 1998. The proportion of subjects with test strip or
monitor claims in 1999 did not differ significantly be-
tween those who commenced use prior to July 1998, and
those who did so between July 1998 and December
1998; among new users of monitors, insulin users and
non-users were equally likely to have monitor or strip
claims in 1999. Insulin users had a higher number of
claims per person. CONCLUSIONS: Although extended
coverage increased new glucose monitor use in insulin us-
ers and non-users, overall use by diabetics remained rela-
tively low. New and established users were equally likely
to sustain use in 1999. As new technology becomes avail-
able for glucose monitoring, claims data offer a method
of identifying the potential target population and esti-
mating the likely impact of coverage policy changes on
utilization and costs.
Average
Bootstrapping 95%
confidence level
Total costs per patient and
year [DM] 5,539 5,184–5,894
Total costs for Germany [DM] 21 billion 19,5–22,5 billion
HbA1c 7.84 7.63–8.07
Treatment type [%]
Diet 19.4 16.7–22.1
OAD 53.0 49.6–56.4
Insulin 27.6 24.5–30.7
PDB5
THE ECONOMIC BURDEN OF TYPE 2 DIABETES 
ON THE INDIVIDUAL
Holmes J1, Bottomley J2, Gillam S3, Murphy M4
1Economists Advisory Group (EAG), London, UK; 2SmithKline 
Beecham Pharmaceuticals, Hertfordshire, UK, 3The King’s Fund, 
London, UK, 4British Diabetic Association, London, UK
OBJECTIVE: To estimate the personal expenditure and
lost earnings borne by individuals as a result of Type 2
Diabetes. METHOD: A postal questionnaire was sent to
a random sample of 750 Type 2 Diabetes patients and
their informal carers at each of 4 UK clinical centres as
part of the T2ARDIS cost of illness survey. The samples
were drawn from registers including patients receiving
only primary care as well as those receiving hospital care.
Personal expenditure data were collected from the ques-
tionnaire. Lost earnings were estimated for working age
respondents who reported that they were not working
full time because of their diabetes or because of the de-
mands of caring for someone with Type 2 Diabetes. Age
and gender specific average earnings were then applied,
adjusted downwards for national unemployment. RE-
SULTS: A total of 1578 patients (52.6%) and 500 regu-
lar informal carers responded to the survey. There was
no significant response bias amongst the patients, based
on checks of non-respondent demographics and treat-
ment regimes. The patients (n  1578) reported average
personal expenditure of £234 per year (SD 1486), but
those with an informal carer (n  500) reported higher
average expenditure at £384 per year (SD 2195). A wide
range of expenditure items was reported but the largest
single category of expenditure was private healthcare and
OTC medication. Carers themselves (n  500) reported
an average of £161 (SD 549) personal expenditure per
year. The lost earnings of patients and carers combined
were estimated at £568 (SD 3463) per patient (n  1578),
and £1441(SD 5620) per patient with a carer (n  500).
CONCLUSION: People with Type 2 Diabetes and their
informal carers incur a substantial economic burden, be-
fore consideration of the impact on their quality of life.
This burden includes significant personal expenditure,
particularly on private healthcare, and significant lost
earnings as a result of the condition.
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THE FINANCIAL EFFECTS OF INTERFACE 
AGREEMENTS FOR DIABETES MELLITUS: 
SOCIOECONOMIC RELEVANCE OF INTENSIVE 
CONTROLLED INSULIN THERAPY WITH 
INSULIN LISPRO COMPARED TO REGULAR 
HUMAN INSULIN
Kilburg A1, Clouth J2, Daniel D1, Kirchhoff D1, Rychlik R1
1Institute of Empirical Health Economics, Burscheid, Germany; 
2Lilly Deutschland GmbH, Bad Homburg, Germany
OBJECTIVES: To assess the costs of intensive controlled
therapy with insulin lispro compared to regular human
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insulin in different stages of health care. The background
of the study was that a few sickness insurance funds have
made interface agreements which defined patient referral
up the ladder on the basis of HbA1c levels to improve the
care of diabetes mellitus patients. The study focused on
whether patients under treatment with insulin lispro could
be kept in primary care. The hypothesis was that the
more frequent patients were referred to a specialist or
hospitalized the higher the costs they incur. The explor-
atory study was put together to get some basic costings
from which a hypothesis can be generated for a prospec-
tive naturalistic study. METHODS: A Markov model
was used to estimate the expected costs between the two
therapies. Patients with type 1 and type 2 diabetes melli-
tus were included. Estimates of resource utilization were
obtained from published studies and from an expert panel
of 19 general practitioners (GPs) and diabetologists. Each
expert retrospectively documented the resource utiliza-
tion of three defined patients for each health care level
over a period of one year. Only direct costs were consid-
ered (perspective from statutory health insurances). RE-
SULTS: The results revealed a clear difference of DM
468 in annual costs per patient in favor of insulin lispro
under actual treatment conditions (insulin lispro DM
2,994; regular human insulin DM 3.462). According to
guidelines resulting treatment costs for both cohorts were
roughly identical (insulin lispro DM 3,568, regular hu-
man insulin DM 3,581). CONCLUSION: Based on the
assumptions used in the model, intensive controlled treat-
ment of diabetic patients with insulin lispro under actual
treatment conditions results in lower costs due to a lower
probability of hospitalization and lower GPs treatment
costs, in spite of the initially higher price of insulin lispro.
These differences will be the subject of a prospective co-
hort study with a naturalistic design, testing the main hy-
pothesis whether hospitalization costs can be reduced by
treatment with insulin lispro and whether the patients
can be kept in primary care settings with improved care
and lower costs.
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HEALTH RELATED QUALITY OF LIFE IN
TYPE 2 DIABETES
Holmes J1, Bottomley J2, Gillam S3, Murphy M4
1Economists Advisory Group (EAG), London, UK; 2SmithKline 
Beecham Pharmaceuticals, Hertfordshire, UK, 3The King’s Fund, 
London, UK, 4British Diabetic Association, London, UK
OBJECTIVE: To identify the impact of Type 2 Diabetes
on Health-related Quality of Life (HrQoL) using the Eu-
roQol (EQ-5D). METHOD: The EQ-5D questionnaire
was sent by post to a random sample of 750 Type 2 Dia-
betes patients at each of 4 UK clinical centres as part of
the T2ARDIS cost of illness survey. The samples were
drawn from registers including patients receiving only
primary care as well as those receiving hospital care. The
impact of complications of Type 2 diabetes on HrQoL
was evaluated. Comparison of the EQ-5D index findings
was made with data from the 1996 Health Survey of En-
gland. RESULTS: A total of 1510 EQ-5D index ques-
tionnaires were returned (50.3%). There was no signifi-
cant response bias, based on checks of non-respondent
demographics and treatment regimes. The T2ARDIS re-
spondents demonstrated significantly more problems (“some
problems” plus “extreme problems”) than the general
population across each of the five domains of the EQ-5D
index. The deficit in HrQoL versus the general popula-
tion was most marked in the 45 age group. The compli-
cations of diabetes were also found to be associated with
reduced HrQoL; pairs of respondents matched for 10
year age group, gender and smoking were identified in
subgroups representing those with no complications, mi-
crovascular complications, macrovascular complications,
and both micro and macrovascular complications (n 
89 in each subgroup). All the complications subgroups
showed significantly lower HrQoL than the subgroup
with no complications (P  0.01 in all cases). The mean
EQ-5D Index scores for the four groups were: none 
0.79, micro  0.7, macro  0.7 and both  0.49. CON-
CLUSION: People with Type 2 Diabetes experience sig-
nificantly lower HrQoL than their peers in the general
population, particularly in the younger age groups. Mi-
crovascular and macrovascular complications are associ-
ated with even lower levels of HrQoL. Prevention of
complications may enhance quality of life in Type 2 diabetes.
GENDER-SPECIFIC DISORDERS
PGS1
ALOPECIA, PSYCHOLOGICAL DISTRESS AND 
QUALITY OF LIFE
Taïeb C, Smadja C
Pharmaco-Economic programs, Pierre Fabre Laboratories, 
Boulogne, France
The loss of hair either due to ageing, pathology or a drug
therapy, often proves to be badly supported by those
who suffer from it. OBJECTIVE: Evaluate the psycho-
logical impact and the consequences on Quality of Life of
hair loss. METHOD: Literature review. RESULTS: This
review confirms that loss of hair has an important psy-
chosocial impact. The lack of self-esteem, emotional re-
actions, frustrations and social inabilities are recurrent
terms. The change of Quality of Life and of satisfaction
develop as much as the degree of hair loss. Subjects with
advanced alopecia report twice as much socio-emotional
effect as those with a mild and/or moderate alopecia.
Women suffer more of anxiety, of low self-estimation
and unsatisfaction of the body image and of their general
Quality of Life. Young people with early hair loss prove
to be more psychologically sensitive. Children are also
vulnerable and some aggressiveness is noticed. A sound
psychological morbidity can be associated to alopecia. It
can induce distress, which, in some cases, changes into a
real depression. Koo has identified, on the basis of DSM-
III-R, near to 9% of major depression within a sampling
